Literature DB >> 1997003

Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation.

P M Dansette1, C Amar, P Valadon, C Pons, P H Beaune, D Mansuy.   

Abstract

Tienilic acid (TA) is metabolized by human liver microsomes in the presence of NADPH with the major formation of 5-hydroxytienilic acid (5-OHTA) which is derived from the hydroxylation of the thiophene ring of TA. Besides this hydroxylation, TA is oxidized into reactive metabolites which covalently bind to microsomal proteins. Oxidation of an isomer of tienilic acid (TAI), bearing the aroyl substituent on position 3 (instead of 2) of the thiophene ring, by human liver microsomes, gives a much higher level of covalent binding to proteins. Both covalent binding of TA and TAI metabolites are almost completely suppressed in the presence of glutathione. These three activities of human liver microsomes (TA 5-hydroxylation, covalent binding of TA and TAI metabolites) seem dependent on the same cytochrome P450 of the IIC subfamily, since (i) antibodies against human liver cytochromes P450 IIC strongly inhibit these three activities, (ii) there is a clear correlation between these activities in various human liver microsomes, and (iii) TA acts as a competitive inhibitor for TAI activation into electrophilic metabolites (Ki approximately equal to 25 microM) and TAI inhibits TA 5-hydroxylation. However cross inhibition experiments indicate that tienilic acid hydroxylation and mephenytoin hydroxylation, a typical reaction of some human liver P450 IIC isoenzymes, are not catalysed by the same member of the P450 IIC subfamily.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997003     DOI: 10.1016/0006-2952(91)90627-h

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.

Authors:  Darcy R Flora; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2011-12-28       Impact factor: 3.922

Review 4.  Cytochromes P450 and drug toxicity. Immunological consequences.

Authors:  D Mansuy
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

5.  Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.

Authors:  Yakov M Koen; Diganta Sarma; Todd D Williams; Nadezhda A Galeva; R Scott Obach; Robert P Hanzlik
Journal:  Chem Res Toxicol       Date:  2012-04-10       Impact factor: 3.739

Review 6.  Drug-induced immunotoxicity.

Authors:  P M Dansette; E Bonierbale; C Minoletti; P H Beaune; D Pessayre; D Mansuy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.441

7.  Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.

Authors:  Hsia-lien Lin; Haoming Zhang; Christine Medower; Paul F Hollenberg; William W Johnson
Journal:  Drug Metab Dispos       Date:  2010-11-10       Impact factor: 3.922

8.  Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes.

Authors:  Jennifer L Goldman; Yakov M Koen; Steven A Rogers; Kelin Li; James S Leeder; Robert P Hanzlik
Journal:  Drug Metab Dispos       Date:  2016-07-25       Impact factor: 3.922

Review 9.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

Review 10.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.